rotid terminus). We present the initial results on the first 10 cases in Europe (at 2 institutions in the United Kingdom) that employed the PulseRider device in the treatment of middle cerebral artery and anterior communicating artery as well as terminal bifurcation aneurysms.
Methods

Case Selection
Patients whose aneurysms were intended to be treated with the PulseRider device at 2 institutions in the United Kingdom, Leeds General Infirmary and The Walton Centre, were identified prospectively. Bifurcation aneurysms that were broad necked were considered candidates for treatment with the novel device. Both institutional and departmental approvals were gained for the undertaking of this case series.
All patients had an unruptured wide-necked bifurcation aneurysm (de novo or recurrent) at the basilar tip, terminal carotid artery, anterior cerebral artery, or middle cerebral artery, based on cerebral angiography findings. Each case was discussed in detail at our institutions' Neuro-vascular Multi-Disciplinary Team (MDT) meeting, attended by the vascular neurosurgeons and interventional neuroradiologists. This was followed by discussion with the individual patients themselves. In all 10 patients, the aneurysm was deemed unsuitable for simple balloon-or Woven EndoBridge (WEB)-assisted coil embolization, based on anatomical and geometric considerations, but the PulseRider was selected as an appropriate treatment approach. In 7 cases craniotomy and clipping was also deemed technically feasible (Cases 1-5, 8, and 9; Table 1 ). Both treatment options were discussed with these 7 patients in terms of benefits and risks, and all 7 elected to undergo the PulseRider endovascular technique. The remaining 3 patients (Cases 6, 7, and 10; Table 1 ), for whom there was no surgical alternative, underwent the PulseRider technique. All cases were treated electively.
Analysis
Patient demographics, procedural details, complications, immediate and 6-month angiographic outcomes, and 6-month follow-up assessment of global disability using the modified Rankin Scale 34,45 were recorded prospectively.
PulseRider Device
The PulseRider device is a self-expanding nitinol implant ( Fig. 1) that is delivered on a stainless steel delivery wire within any commercially available 0.021-inch-diameter microcatheter. The device is fully retrievable and can be repositioned and torqued to fit the relevant anatomy. It contains significantly less metal than a conventional stent, with the majority of the surface area focused at the neck of the aneurysm. The device is available in both Y-and T-configurations ( Fig. 1) to fit the geometry of the daughter vessels arising at the bifurcation. The device is also available in different diameters and lengths. The device provides coil support while maintaining daughter vessel intraluminal patency (Fig. 2 ).
Coil Embolization Technique
All patients underwent cerebral angiography with 3D reconstruction as deemed necessary prior to the intervention. Patients were pretreated the evening before the procedure with clopidogrel (600 mg orally) and aspirin (600 mg orally). All procedures were performed under general endotracheal anesthesia. After obtaining percutaneous access (transfemoral in all cases), intravenous heparin was administered and an activated clotting time was obtained to achieve a level 2-2.5 times baseline. A 6-F Envoy guide catheter (Codman Neurovascular) was positioned into the vessel of interest, and working views were obtained in both the anteroposterior and lateral projections following a 3D rotational angiogram. In all cases, either a Prowler Select Plus microcatheter (inner diameter 0.021 inches, Codman Neurovascular) or a Headway 21 microcatheter (MicroVention, Aliso Veijo) was navigated over a 0.014-in microwire and positioned at the neck of the aneurysm. An appropriately sized PulseRider device was then deployed, typically across the neck of the aneurysm with limbs in the daughter vessels. A T-versus Y-configuration device was chosen at the surgeon's discretion based on the geometry of the daughter vessels arising at the bifurcation. The device was initially deployed across the neck, but not detached. In all cases, either an SL-10 microcatheter (Stryker Neurovascular) or Headway 17 microcatheter (MicroVention) was then navigated over a Synchro 0.014-in microwire (Stryker Neurovascular) through the device into the aneurysm. Coil embolization was subsequently performed with follow-up angiography throughout the remainder of coiling as required. The device was detached at the conclusion of coil embolization.
Postprocedure Management
From the 1st day after the procedure, all patients were maintained on once daily oral 75 mg clopidogrel for 3 months and once daily oral 75 mg aspirin life-long. All patients had a minimum overnight stay in the neurosurgical ward, with complete clinical and neurological assessment prior to discharge. Six-month follow-up MR angiography was performed in all cases. Over the study period, followup catheter angiography was performed in all patients. Table 1 summarizes the results of our 10 patients who underwent PulseRider stent-assisted coil embolization of intracranial wide-necked bifurcation aneurysms. There was no procedural rupture or vessel dissection during any of the procedures. There was one case of small nonocclusive thrombus formation in the parent vessel (Case 3 in Table 1, middle cerebral artery) but this was without clinical sequelae and the patient was asymptomatic. In all patients complete angiographic occlusion (Raymond Class 1) was achieved both immediately at the end of the procedure and at 6-month follow-up cerebral angiography. 38 At the 6-month follow-up, 7 patients had no symptoms while 3 patients had some symptoms-left arm numbness (Cases 1 and 4) and headache (Case 9)-but were able to carry out all usual activities (modified Rankin Scale scores of 0 and 1, respectively). Placement of the PulseRider varied depending on the geometry of the aneurysm and the location of the daughter vessels. In some cases, the device was placed at the base with the arch within the side branches; in others, the arch was completely inside the aneurysm. Another alternative was a hybrid placement with one arm of the arch in the daughter vessel and the other arm in the aneurysm. In all cases, coils were successfully deployed inside the aneurysm or remnant and retained by the scaffold (Figs.  3 and 4) .
Results
Discussion
Despite advances in stenting and balloon remodeling techniques, broad-necked aneurysms arising at bifurcations remain a particular challenge to endovascular treatment. These aneurysms occur at the junction of 2 essential branching arteries that must remain patent after embolization.
Several balloon remodeling techniques have been used to treat bifurcation aneurysms: a more compliant balloon (e.g., HyperForm and Transform) can be used to mold the neck of the aneurysm and the origin of bifurcation branches;
4 two balloons can be used instead of one (1 balloon in each of the bifurcated arterial branches); 3 and navigation of the balloon through the circle of Willis to cross and protect the aneurysm neck 13 and the navigation of a duallumen balloon in front of the neck can be used to allow coil deposition through the second lumen of the balloon microcatheter.
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Unassisted coiling or single-stent techniques are frequently insufficient to protect the remaining daughter vessels and prevent coil prolapse leading to arterial occlusion. Indeed, conventional coil therapy was reported as one of the predictors of delayed recurrence and retreatment in a recent study of 209 patients. 19 Over the last decade, various techniques have been introduced to assisted coiling to prevent recurrence and promote reconstruction of the parent vessel. In particular, the use of these techniques has been justified in complex bifurcation and wide-necked aneurysms. The wide-necked aneurysm has demonstrated worsening of occlusion in up to 62.1% of cases in the CLARITY study. 37 More recently, double stenting in a Y or X configuration may be used to treat a subset of wide-necked bifurcation aneurysms. The use of 2 stents in a Y-shaped configuration (Y-stenting) to assist with coil embolization of complex bifurcation aneurysms was first described in 2004. 12 Since that time, several reports have been published that demonstrated acceptable morbidity and mortality rates associated with Y-stenting, and it has been accepted as a safe and reasonable alternative to clip reconstruction for a select subset of challenging aneurysms.
1,7,10,11,14,16,24,29,31,38,40,42,43,46 X-configured stentassisted coiling has been used to treat wide-necked and complex anterior communicating artery aneurysms.
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Recently introduced, flow diversion stenting takes advantage of changing the parent artery/aneurysm sac interface, altering in-flow and out-flow jets, to induce aneurysm thrombosis. 5, 18, 30 However, this method is not ideal in treating bifurcation aneurysms because it would effectively jail one of the limbs of the bifurcation and has been associated with the risk of daughter vessel, side branch, and perforator occlusion. 6, 15, 32 Balloon remodeling techniques and X-and Y-stenting remain technically challenging, require many steps to be performed successfully, and, although feasible, are associated with relatively higher rates of periprocedural morbidity and mortality. 8, 9 Compared with X-and Y-stent reconstruction, the PulseRider has a very low metal-toartery ratio, with the highest density of metal positioned to cover the aneurysm neck and support a coil mass. As a result, there is no jailing of daughter branches, and there is minimal intraluminal hardware that is not opposed to vessel intima. The device is fully retrievable and can be repositioned and recaptured until it is detached with an electrolytic detachment mechanism. This results in a technically easier procedure that is more streamlined, as only one device is required to be positioned to reconstruct the bifurcation. Fewer steps will theoretically result in fewer technical adverse events during the procedure. In addition, employing a single device for vessel reconstruction may provide a higher value (quality vs cost) compared with strategies using multiple devices.
WEB is a new endovascular approach to treating widenecked bifurcation aneurysms by disrupting intrasaccular flow to cause thrombosis. Early data demonstrated complete occlusion rates between 80% and 89% and a 3% to 7% risk of complications, including thromboembolism, WEB retrieval, and inadvertent detachment. 22, 33 The device has been associated with worsening aneurysm occlusion at a rate of 7%. 22 However, it does not address neck reconstruction in some cases. This is true in cases in which daughter branches are part of the aneurysm neck.
The PulseRider device has received European CE Mark approval since 2013. The European CE-approved indication is the treatment of complex intracranial bifurcation aneurysms (with no limitation or specification as to particular vessels). The FDA has granted an investigational device exemption for the clinical trial use of PulseRider for the treatment of wide-necked bifurcation aneurysms, specifically at the basilar tip and carotid terminus. Indeed, there is only one previously published study of PulseRider stents in the US, which assessed 3 patients with widenecked bifurcation aneurysms specifically at the basilar tip or carotid terminus. 41 In our early experience we have found the use of PulseRider to be simple and safe, being readily delivered in a standard method very similar to other available stents, making the procedure more familiar to an operator new to the device. It is conformal and delivered without difficulty through any 0.21-inch microcatheter, even in torturous anatomy. The device is easily recaptured and can be turned by pulling it back into the catheter while torqueing on the device and then redeploying it until it conforms to the specific anatomy. Once deployed across the neck, the device can be crossed readily by navigating a standard coiling microcatheter over a 0.014-inch microwire. Since the majority of the metal mass of the stent is concentrated at the neck, it is likely that patients could be managed safely with shorter dual antiplatelet regimens or even a single antiplatelet medication. Lastly, in our experience the metal support at the neck has proved to be sufficient to support a coil mass.
All cases in our series had an aneurysm neck size greater than 4 mm, which we considered appropriate based on our personal experience. Had the neck size been less than 4 mm, we would have preferred standard or balloon-assisted coil embolization approaches. The PulseRider was only used in those patients in whom the stent could be passed through an adequately sized parent vessel and daughter branches and safely deployed to adequately cover the neck of the aneurysm. This decision was made following meticulous evaluation of the 3D angiographic images. Arterial bifurcation configurations with a T shape and Y shape are both appropriate for PulseRider use. However, based on our limited personal experience, which is still evolving, we have found that if the angle between the daughter branches is too acute (< 60°) the satisfactory deployment of the stent becomes more challenging. We have therefore found that T-shaped and gentle Y-shaped bifurcations with an angle between the daughter branches greater than 60° are most appropriate and correspond to the default stent configurations of the manufacturer (T-shaped and gentle Yshaped). The stent is available in diameters of 2.7-3.5 mm and 3.5-4.5 mm, and lengths of 8.6 mm, 10.6 mm, and 11.1 mm. Therefore, the correct stent for use has to be selected based on a parent vessel size ranging between 2.7 and 4.5 mm in diameter, appropriate vessel length, and adequate branch vessel dimensions (although no specific limitations have been advised by the manufacturer) as well as the neck dimensions that have to be spanned. Intuitively, we will not use the stent in a vessel that is too small to accommodate, which itself depends on the size of stent available. This forms a potential limitation for the device, in that it is only available in 2 configurations with a limited range of sizes.
Limitations of the PulseRider device are that it has no flow-diverting effects that may be seen using braided stents or X-or traditional Y-shaped stents, and also it is a new device with as yet unknown long-term outcomes. Follow-up MRI shows stent artifact and dropout at the level of markers on the device, and catheter angiograms are needed at this stage to assess the stability of the aneurysm. Furthermore, PulseRider has not yet been assessed in an acute setting for the treatment of ruptured aneurysms in our series.
Conclusions
We have presented, to the best of our knowledge, the first case series in Europe and the largest case series to date of the PulseRider device for the treatment of complex wide-necked intracranial bifurcation aneurysms arising from the middle cerebral artery bifurcation, anterior cerebral artery, basilar apex, and carotid terminus. Our early experience demonstrates that PulseRider is a safe adjunct that provides a scaffold at the neck of the bifurcation aneurysm, enabling neck remodeling and coil support while maintaining parent and daughter vessel intraluminal patency. In each of the 10 cases presented, the procedure was successfully completed without aneurysm rupture or vessel dissection. Our early clinical and radiological followup shows good functional outcome and stable complete occlusion rates from the procedure, respectively. Additional clinical work at our institutions is planned to better evaluate the medium-and long-term safety and performance of this novel device.
